Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

Tariffs, and their potential detrimental impacts on vehicle affordability, company profits, global competitiveness, and ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

As Merck gears up for its Q2 earnings, all eyes are on Keytruda, its oncology superstar. Keytruda, accounting for nearly half of Merck’s pharma sales, is anticipated to report Q2 sales of $7.90 ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...